Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NC1Q
|
|||
| Former ID |
DNCL002106
|
|||
| Drug Name |
AMG 172
|
|||
| Indication | Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64] | Phase 1 | [1] | |
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CD70 antigen (CD27-L) | Target Info | Modulator | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TNFalpha Signaling Pathway | ||||
| RANKL Signaling Pathway | ||||
| Reactome | TNFs bind their physiological receptors | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01497821) AMG 172 First in Human Study in Patients With Kidney Cancer. U.S. National Institutes of Health. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug id 721679). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.